These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 30739121)
1. Anti-Diabetogenic Properties of Mineralocorticoid Receptor Antagonists: Implications for Enhanced Safety and Efficacy of Post-Transplantation Pharmacotherapies. Ming Y; Stefano GB; Kream RM; Zhuang Q Med Sci Monit; 2019 Feb; 25():1102-1104. PubMed ID: 30739121 [TBL] [Abstract][Full Text] [Related]
2. Side effects of the calcineurin inhibitor, such as new-onset diabetes after kidney transplantation. Borda B; Lengyel C; Várkonyi T; Kemény E; Ottlakán A; Kubik A; Keresztes C; Lázár G Acta Physiol Hung; 2014 Sep; 101(3):388-94. PubMed ID: 25183511 [TBL] [Abstract][Full Text] [Related]
4. Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients. Penninga L; Wettergren A; Chan AW; Steinbrüchel DA; Gluud C Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD008852. PubMed ID: 22419339 [TBL] [Abstract][Full Text] [Related]
5. Calcineurin inhibitors in renal transplantation: what is the best option? Tanabe K Drugs; 2003; 63(15):1535-48. PubMed ID: 12887261 [TBL] [Abstract][Full Text] [Related]
6. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. Shihab F; Christians U; Smith L; Wellen JR; Kaplan B Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504 [TBL] [Abstract][Full Text] [Related]
7. Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation. Wong TC; Lo CM; Fung JY Expert Opin Emerg Drugs; 2017 Jun; 22(2):123-136. PubMed ID: 28503959 [TBL] [Abstract][Full Text] [Related]
8. Costimulatory Blockade and Use of Mammalian Target of Rapamycin Inhibitors: Avoiding Injury Part 1. Augustine J; Hricik DE Adv Chronic Kidney Dis; 2016 Sep; 23(5):301-305. PubMed ID: 27742384 [TBL] [Abstract][Full Text] [Related]
10. The safety of calcineurin inhibitors for kidney-transplant patients. Malvezzi P; Rostaing L Expert Opin Drug Saf; 2015 Oct; 14(10):1531-46. PubMed ID: 26329325 [TBL] [Abstract][Full Text] [Related]
11. Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation. Asante-Korang A; Carapellucci J; Krasnopero D; Doyle A; Brown B; Amankwah E Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28708333 [TBL] [Abstract][Full Text] [Related]
12. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus. Fuchs U; Zittermann A; Ensminger SM; Schulz U; Gummert JF Transpl Immunol; 2014 Aug; 31(2):87-91. PubMed ID: 24932812 [TBL] [Abstract][Full Text] [Related]
13. Effects of mTOR and calcineurin inhibitors combined therapy in Epstein-Barr virus positive and negative Burkitt lymphoma cells. Wowro SJ; Schmitt KRL; Tong G; Berger F; Schubert S Int Immunopharmacol; 2016 Jan; 30():9-17. PubMed ID: 26613512 [TBL] [Abstract][Full Text] [Related]
14. Optimization of the use of Calcineurin inhibitors in liver transplantation. de Mare-Bredemeijer EL; Metselaar HJ Best Pract Res Clin Gastroenterol; 2012 Feb; 26(1):85-95. PubMed ID: 22482528 [TBL] [Abstract][Full Text] [Related]
15. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial. Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603 [TBL] [Abstract][Full Text] [Related]
16. Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation. Alamo JM; Barrera L; Casado MD; Bernal C; Marin LM; Suarez G; Sanchez-Moreno L; Jimenez R; Suarez-Grau JM; Sousa JM; Cordero E; Gomez-Bravo MA Transplant Proc; 2009; 41(6):2181-3. PubMed ID: 19715866 [TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive treatment and progression of histologic lesions in kidney allografts. Morales JM Kidney Int Suppl; 2005 Dec; (99):S124-30. PubMed ID: 16336565 [TBL] [Abstract][Full Text] [Related]
18. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis. Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806 [TBL] [Abstract][Full Text] [Related]
19. The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity: a multicenter randomized, double-blind, clinical trial (the SPIREN trial). Mortensen LA; Thiesson HC; Tougaard B; Egfjord M; Fischer ASL; Bistrup C BMC Nephrol; 2018 May; 19(1):105. PubMed ID: 29724188 [TBL] [Abstract][Full Text] [Related]
20. Benefit-risk assessment of sirolimus in renal transplantation. Kuypers DR Drug Saf; 2005; 28(2):153-81. PubMed ID: 15691225 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]